Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)

NCT03326102 is registered in ClinicalTrials.gov with Daehwa Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03326102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03326102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2018
Completion date
December 13, 2022
Enrollment
72 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic breast cancer